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!
Underlying mathematical model of tuberculosis burden in 
children !
A mechanistic mathematical model that uses estimates of adult tuberculosis prevalence to 
model the process of infection and progression to disease in different age-groups was used to 
generate estimates of latent infection and tuberculosis incidence in 180 countries in 2013. The 
model has been previously published and subsequently extended from the 22 high 
tuberculosis burden countries to a global model covering 180 countries.  
 
The model has a number of uncertain data and natural history inputs, and the uncertainty 
inherent in these quantities is represented by generating a sample of 10,000 outputs running 
the model across a Latin hypercube sample from the distributions characterizing these input 
values. A summary is provided below. 
 
Summary of methods 
 
 
Figure 1: Overview of modelling logic. Diamonds represent data sources, squares represent numbers 
estimated at each stage, and stadiums represent modelling stages. !
Description of data used 
 
We obtained data on country demography for 2013 from UN ESA, Population Division. 
Where necessary, 5-year age categories were disaggregated under the assumption of 
uniformly distributed ages. These data were used to generate the number of children at risk in 
each country by age. 
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WHO estimates of adult tuberculosis prevalence were obtained from for 2014, together with 
95% uncertainty bounds. Uncertainty in per-capita prevalence was represented by gamma 
distributions, parameterised by taking the quoted ranges defined by the upper and lower 
bounds as 1.96 x the standard deviation, and the quoted point estimate as the mean. WHO 
notification data from 2010 were used to estimate the proportion of incident tuberculosis that 
is smear positive for the community ARI estimate. The same estimate was used for all 
countries to avoid bias resulting from different case detection infrastructures etc. 
 
BCG vaccination coverage estimates were obtained for 2014 from WHO. The BCG 
vaccination coverages were used to determine the fraction of children whose risks of 
progression from infection to disease were moderated by BCG.  
 
HIV prevalence estimates in those aged under 15 were available for 82 countries from 
UNAIDS, together with 95% uncertainty bounds. Countries for which there were not 
estimates reported from this source were assumed to have negligible HIV prevalence in those 
under 15 years of age. Uncertainty in the prevalences was represented by gamma 
distributions, parameterised by taking the quoted ranges defined by the upper and lower 
bounds were taken as 1.96 x the standard deviation, and the quoted point estimate as the 
mean. This HIV prevalence was assumed to be uniform by age in those under 15. Degree of 
immunosuppression or ART was not considered.  
 
Country linking and exclusions 
 
The WHO tuberculosis estimate and notification data were linked with the demographic, HIV, 
and BCG sets by 3 letter ISO code where possible, and by hand otherwise. Various countries 
were excluded where it was not possible to link them across the data. The WHO version of 
country names was used. 
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Figure 2: The 180 countries included in our analysis (color by estimated per-capita tuberculosis 
incidence) 
 
Summary of differences from previous work 
 
The largest difference is the set of countries to which the method is applied. Here, we apply 
the model to a set of 180 countries and use tuberculosis data from 2014; whereas in our 
previously published report (see reference in main article), we considered only the 22 highest 
burden tuberculosis countries (HBCs), using data largely from 2010.  
 
We only consider the ‘community’ model of infection in this work, as data to inform the 
household method were not available for a large enough number of countries. We also shifted 
from using the latitude of a country’s capital to the latitude of a country’s centroid in the 
model variant with latitude variation in BCG efficacy. 
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Analysis of drug-resistance patterns 
Data availability by region !
!
Figure 3: Countries with data on resistance to first-line anti-tuberculosis drugs in new cases !
!!
Figure 4: Countries with data resistance to second-line anti-tuberculosis drugs.   
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Nearest neighbor construction & interpretation of survey data 
 
!!!
Figure 5: Ranked implied design effects in survey data on MDR in new cases based on reported 
confidence intervals and sample size. Red line at 1. 
 
!
Figure 6: The network of 5 nearest-neighbors used for imputing drug resistance patterns for countries 
without data.   
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WHO regions used 
 
The three key differences between the two sets of regions are (i) the split between Central and 
Eastern Europe based on well-studied and known differences in MDR-TB epidemiology, (ii) 
the separate region of high-income countries across the world who are expected to have 
stronger health systems that are closer to universal health coverage (considered proxy for 
lower levels of acquired drug resistance), and (iii) the split of the African region into high and 
low HIV prevalence (HIV being a key determinant of TB burden). The nine epidemiological 
regions are African countries with high HIV prevalence, African countries with low HIV 
prevalence, Central Europe, Eastern Europe, high-income countries, Latin America, the 
Eastern Mediterranean Region (excluding high-income countries), the South-East Asia 
Region (excluding high-income countries) and the Western Pacific Region (excluding high-
income countries). 
!
Figure 7: Map of standard WHO regions 
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!!
Figure 8: Map of WHO epidemiological regions used for resampling scheme. 
Missing data 
 
With complete data on the counts (!!,!! ,!! ,!!) of susceptible, HMR, RMR, and MDR 
tuberculosis we assumed a !"#(1,1,1,1) (i.e. flat) prior on the proportions. Since this is 
conjugate to the multinomial distribution, the posterior was therefore !"#(1+ !!, 1+!! , 1+ !! , 1+ !!). 
 
When, additionally (and e.g.) data was available on the total count !′ = !!′+ !!′+ !!′+!!′, and the number MDR (!!′,!!′,!!′ all missing due to incomplete DST), we sampled 
from the posterior summing over all possible unobserved missing counts compatible with the 
total. In effect, this amounts to a draw from a mixture of Dirichlet distributions. In 
combination 
 ∝ !!!!′!!′!!′!!′ ×!"#(1+ !! + !!′, 1+ !! + !!′, 1+ !! + !!′, 1+ !! + !!′) 
 
Gibbs sampling was used to sample from these distributions using every 30th draw in a chain 
of 30,000 iterations (after a burn-in of 1,000 iterations). 
 
Other combinations of missing drug resistance counts described in the article were handled 
analogously. 
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Source of data for country estimates 
 
 
 
Figure 9: Source of data for each country used in first-line drug-resistance estimates 
 
 
Figure 10: Source of data for each country used in second-line drug-resistance estimates
Data sources for 
1st−line DR estimates
neighbour
regional
self
Not included
Data sources for 
2nd−line DR estimates
neighbour
regional
self
Not included
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Supplementary results 
 
Tables 
 
Table 1: Percentage of incident tuberculosis in children by resistance type in 2014. IQR in brackets. 
 
! %"of"incident"children"by"resistance"type! %"of"incident"MDR"children"by"resistance"type!
 S INH RIF MDR MDR# FQR SLR XDR 
AFR 91.6 [91.2 - 92.0] 4.9 [4.5 - 5.5] 0.9 [0.8 - 1.0] 2.5 [2.2 - 2.7] 80.5 [77.8 - 82.9] 7.2 [5.7 - 9.1] 8.8 [6.5 - 11.4] 3.0 [2.4 - 3.7] 
AMR 92.9 [92.4 - 93.2] 4.7 [4.4 - 5.0] 0.4 [0.3 - 0.6] 2.0 [1.8 - 2.3] 56.7 [47.7 - 66.0] 11.1 [8.5 - 13.9] 20.9 [16.9 - 25.7] 9.9 [7.5 - 12.5] 
EMR 85.1 [83.5 - 86.4] 8.7 [7.8 - 9.7] 1.7 [1.3 - 2.2] 4.3 [3.8 - 5.0] 65.2 [60.9 - 68.7] 19.2 [16.4 - 22.5] 9.1 [7.4 - 11.5] 5.6 [4.4 - 7.3] 
EUR 70.9 [69.6 - 72.4] 11.9 [11.3 - 12.5] 1.3 [1.2 - 1.5] 15.8 [14.7 - 16.7] 48.0 [40.7 - 54.4] 17.4 [13.5 - 24.0] 23.1 [18.7 - 29.0] 8.0 [7.2 - 8.9] 
SEA 89.9 [89.6 - 90.3] 7.3 [7.0 - 7.5] 0.6 [0.6 - 0.7] 2.2 [2.0 - 2.3] 60.9 [52.2 - 69.5] 17.1 [15.5 - 18.8] 18.8 [10.6 - 26.8] 3.1 [2.6 - 3.8] 
WPR 84.4 [84.0 - 84.8] 10.5 [10.2 - 10.8] 1.2 [1.1 - 1.3] 3.9 [3.7 - 4.1] 55.3 [53.2 - 57.8] 25.0 [23.4 - 26.6] 12.4 [11.5 - 13.3] 7.0 [6.3 - 7.6] 
GLOBAL 89.3 [89.0 - 89.6] 6.9 [6.6 - 7.1] 0.9 [0.8 - 1.0] 2.9 [2.7 - 3.1] 65.9 [62.8 - 68.6] 15.4 [14.4 - 16.6] 13.8 [11.4 - 16.5] 4.7 [4.3 - 5.1] !! !
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Table 2: Estimates of incident tuberculosis in children under 5 by drug resistance type and WHO region, 2014. 
 
Total 
Estimates of incident tuberculosis in children <5 by drug 
resistance type 
Estimates of incident MDR-tuberculosis in children  <5 
by drug resistance type 
DS HMR RMR MDR MDR# FQR SLR XDR 
AFR 181,000 [181,000 - 181,000] 166,000 [166,000 - 166,000] 9,030 [9,030 - 9,030] 1,560 [1,560 - 1,560] 4,380 [4,380 - 4,380] 3,500 [3,500 - 3,500] 304 [304 - 304] 376 [376 - 376] 130 [130 - 130] 
AMR 12,100 [12,100 - 12,100] 11,200 [11,200 - 11,200] 564 [564 - 564] 56 [56 - 56] 253 [253 - 253] 139 [139 - 139] 28 [28 - 28] 53 [53 - 53] 25 [25 - 25] 
EMR 38,400 [38,400 - 38,400] 32,700 [32,700 - 32,700] 3,320 [3,320 - 3,320] 666 [666 - 666] 1,680 [1,680 - 1,680] 1,080 [1,080 - 1,080] 322 [322 - 322] 152 [152 - 152] 95 [95 - 95] 
EUR 6,770 [6,770 - 6,770] 4,790 [4,790 - 4,790] 815 [815 - 815] 92 [92 - 92] 1,070 [1,070 - 1,070] 496 [496 - 496] 188 [188 - 188] 245 [245 - 245] 86 [86 - 86] 
SEA 143,000 [143,000 - 143,000] 128,000 [128,000 - 128,000] 10,300 [10,300 - 10,300] 883 [883 - 883] 3,080 [3,080 - 3,080] 1,810 [1,810 - 1,810] 521 [521 - 521] 508 [508 - 508] 96 [96 - 96] 
WPR 45,900 [45,900 - 45,900] 38,800 [38,800 - 38,800] 4,840 [4,840 - 4,840] 548 [548 - 548] 1,790 [1,790 - 1,790] 990 [990 - 990] 445 [445 - 445] 221 [221 - 221] 124 [124 - 124] 
GLOBAL 435,000 [435,000 - 435,000] 389,000 [389,000 - 389,000] 29,500 [29,500 - 29,500] 3,920 [3,920 - 3,920] 12,700 [12,700 - 12,700] 8,330 [8,330 - 8,330] 1,940 [1,940 - 1,940] 1,720 [1,720 - 1,720] 596 [596 - 596] !! !
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Maps of incidence and infection burden 
 
Figure 11: Percentage of tuberculosis disease in children by first-line resistance types, 2014 
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Figure 12: Percentage of MDR tuberculosis disease in children by second-line resistance type, 2014 
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Figure 13: Tuberculosis incidence in children by first-line resistance type, 2014  
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Figure 14: Tuberculosis incidence in children by second-line resistance type, 2014  
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!!
!!
Figure 15: LTBI in children by first-line resistance type, 2014  
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Figure 16: LTBI in children by second-line resistance type, 2014 
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